Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

Buy Legend Biotech (LEGN): new Carvykti CARTITUDE-4 data show better survival and <1% Parkinsonism; upside at 3.0x ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

LB2501: Promising Phase 1 Trial of In Vivo CAR-T Data Demonstrate High Response Rates in B-cell Malignancies ...

NewLimit’s lead liver combo has proven its worth in preclinical models, Kimmel told Fierce, with the ability to boost ...

If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...

It is finally bouncing back after several challenging years.